Navigation Links
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
Date:11/22/2011

SINGAPORE, Nov. 22, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 2 studies for its JAK2 inhibitor pacritinib (SB1518) and histone deacetylase inhibitor pracinostat (SB939) demonstrate promising activity in patients with myelofibrosis (MF). Results will be presented at the 53rd ASH Annual Meeting and Exposition in San Diego, Calif.

"Pacritinib has been well tolerated and has shown activity in alleviating MF-associated splenomegaly and constitutional symptoms with lack of myelosuppression. This is critical to MF patients with impaired hematopoiesis," said Tamar Howson, interim CEO and board member of S*BIO. "Pracinostat showed activity in reducing spleen and/or liver size in MF patients."

Poster: 282, Session:  634. Myeloproliferative Syndromes: Clinical Advances I, Time: 8:15 a.m. PST, Monday, Dec. 12, 2011, Location: Room 6B (San Diego Convention Center)
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
Pacritinib showed promising efficacy in alleviating MF-associated splenomegaly and constitutional symptoms at a dose that induces minimal myelosuppression.  Once-daily dosing is well tolerated, with manageable GI toxicity as the main side effect.  Given the lack of myelosuppression with pacritinib, this JAK2 inhibitor is of particular importance for MF patients with impaired hematopoiesis, especially those patients with thrombocytopenia and anemia.

Poster: 3863, Session: 634. Myeloproliferative Syndromes: Clinical Advances I, Time: 6-8 p.m. PST, Monday, Dec. 12, 2011, Location: Hall GH (San Diego Convention Center)
Therapy with the Histone De
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Novel surface triples stem-cell growth in culture
3. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
4. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
5. Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
6. Carbon nanotube muscles generate giant twist for novel motors
7. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
8. Wideband Antenna for Novelda Nanoscale Impulse Radar
9. Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment
10. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... , , Alberta Centre ... health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ ... how technologies like nanotechnology, biomaterials and microfluidics can play a ... help promote health and improve the quality, cost and outcomes ...
... , DALLAS, Dec. 3 ... Bulletin Board: ACCP), today provided an update on its European ... mucositis, a debilitating side effect of radiation treatment and chemotherapy. ... European countries, including the UK, Germany, Italy, Norway, Greece and ...
... , HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, ... and services for drug discovery and life sciences research, today ... systems. Living Image software drives the more than 800 Caliper ... features advanced spectral unmixing tools to enhance fluorescent sensitivity and ...
Cached Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... land managers have a new synthesis of recent research ... (MMC) forests in the two states. , The ... Oregon and Washington: A Synthesis of the Relevant Biophysical ... technical report published by the U.S. Forest Service,s Pacific ... request from managers for a synthesis of the large ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
... Biotechnology and Biological Sciences Research Council (BBSRC) has launched ... ), a devastating fungus that threatens our third most ... of fast-track research funding has been awarded to gather ... to provide genetic clues about some ash trees, natural ...
... do for science if they weren,t, well, green? , That,s ... when they engineered a green alga used commonly in laboratories, ... by producing six different colored fluorescent proteins in the algae ... be all the rage this year for running shoes and ...
... Looking at the transformation of a fly larva into ... mechanisms that trigger puberty. A study conducted on the ... the Institute for Research in Biomedicine (IRB Barcelona) led ... as key to the relationship between hormones that control ...
Cached Biology News:Bioscience to battle ash dieback 2Bioscience to battle ash dieback 3Biologists produce rainbow-colored algae 2IRB Barcelona researchers discover mechanism that regulates steroid hormone production in Drosophila 2
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: